Last Thursday, Fibrocell Science, Inc. (OTC:FCSC) announced it would participate in the Oppenheimer 22nd Annual Healthcare Conference scheduled for December 13-14, 2011 in New York. Investors, however, did not seem too impressed and FCSC stock did not change a wit that day.
On the next day, by contrast, FCSC gained 2.27% to $0.45 on a two-month high volume of 803 thousand, which also marked a four-fold increase over the daily average trading volume.
On Nov. 23, FCSC announced it would also be appearing on the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference scheduled to take place on Dec. 6 in San Francisco. Again, investors remained indifferent and FCSC closed the session without gaining a single cent.
As it seems, market players would rather take a look at the company’s presentations on both conferences before embarking on further actions. Indeed, apart from the two announcements, FCSC provided no details whatsoever with regard to the nature of its presentations. Therefore, increased interest in FCSC stock, if any, appears to be fairly dependent upon what the company will actually present both tomorrow and on Dec. 14.
Fibrocell Science, Inc. pretends to be a biotechnological company which specializes in developing regenerative cell therapy for various scientific and medical applications. As of Sep. 30, its financial condition includes:
- cash reserves of approx. $15 million;
- working capital surplus of $7.8 million;
- $159K in revenue as compared to $244K in Q3 2010;
- operating loss in excess of $5.7 million.
